JP2021501596A5 - - Google Patents

Download PDF

Info

Publication number
JP2021501596A5
JP2021501596A5 JP2020524540A JP2020524540A JP2021501596A5 JP 2021501596 A5 JP2021501596 A5 JP 2021501596A5 JP 2020524540 A JP2020524540 A JP 2020524540A JP 2020524540 A JP2020524540 A JP 2020524540A JP 2021501596 A5 JP2021501596 A5 JP 2021501596A5
Authority
JP
Japan
Prior art keywords
expansion
lymphocytes
interleukin
apc
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020524540A
Other languages
English (en)
Japanese (ja)
Other versions
JP7357613B2 (ja
JP2021501596A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2018/080343 external-priority patent/WO2019086711A1/en
Publication of JP2021501596A publication Critical patent/JP2021501596A/ja
Publication of JP2021501596A5 publication Critical patent/JP2021501596A5/ja
Application granted granted Critical
Publication of JP7357613B2 publication Critical patent/JP7357613B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020524540A 2017-11-06 2018-11-06 リンパ球の拡大方法 Active JP7357613B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762582163P 2017-11-06 2017-11-06
US62/582,163 2017-11-06
PCT/EP2018/080343 WO2019086711A1 (en) 2017-11-06 2018-11-06 Method for expansion of lymphocytes

Publications (3)

Publication Number Publication Date
JP2021501596A JP2021501596A (ja) 2021-01-21
JP2021501596A5 true JP2021501596A5 (https=) 2021-10-28
JP7357613B2 JP7357613B2 (ja) 2023-10-06

Family

ID=64332272

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020524540A Active JP7357613B2 (ja) 2017-11-06 2018-11-06 リンパ球の拡大方法

Country Status (7)

Country Link
US (1) US20200338125A1 (https=)
EP (1) EP3707245A1 (https=)
JP (1) JP7357613B2 (https=)
CN (1) CN111801415A (https=)
AU (1) AU2018361561C1 (https=)
CA (1) CA3081479A1 (https=)
WO (1) WO2019086711A1 (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020095113A1 (en) 2018-11-05 2020-05-14 Ludwig Institute For Cancer Research Ltd Humanized and variant tgf-beta1 specific antibodies and methods and uses thereof
CN113613726B (zh) 2018-11-05 2025-07-15 路德维格癌症研究所有限公司 人源化和变体TGF-β3特异性抗体及其方法和用途
CA3145196A1 (en) * 2019-06-24 2020-12-30 H. Lee Moffitt Cancer Center And Research Institute, Inc. A peptide-based screening method to identify neoantigens for use with tumor infiltrating lymphocytes
JP7337373B2 (ja) * 2019-07-29 2023-09-04 サイアス株式会社 抗原特異的ｔ細胞の製造方法
JP2023509388A (ja) * 2019-12-18 2023-03-08 セービーオ アクティーゼルスカブ 治療用途の腫瘍浸潤性リンパ球を培養するための改善プロセス
US12365871B2 (en) 2020-04-28 2025-07-22 Lyell Immunopharma, Inc. Methods for culturing cells
JP7785699B2 (ja) * 2020-05-29 2025-12-15 シャンハイ ジュンセル セラピューティクス カンパニー リミテッド 腫瘍浸潤リンパ球の種細胞培地及びその使用
EP4192941A1 (en) 2020-08-07 2023-06-14 Neogene Therapeutics B.V. Methods to enrich genetically engineered t cells
US20240209313A1 (en) * 2020-08-17 2024-06-27 Northwestern University B-cell based immunotherapy for the treatment of glioblastoma and other cancers
CN114901805B (zh) 2020-11-19 2023-07-25 苏州沙砾生物科技有限公司 肿瘤浸润淋巴细胞的培养方法及其用途
CN112501308B (zh) * 2020-11-30 2025-10-10 中国水产科学研究院珠江水产研究所 一组鳖科动物线粒体全基因组扩增通用引物
CN118480505A (zh) * 2020-12-24 2024-08-13 苏州沙砾生物科技有限公司 肿瘤浸润淋巴细胞的制备方法及其用途
CN114686430A (zh) * 2020-12-31 2022-07-01 上海赛比曼生物科技有限公司 一种制备til的方法
WO2022159460A1 (en) * 2021-01-20 2022-07-28 Neogene Therapeutics B.V. Engineered antigen presenting cells
WO2022166947A1 (zh) * 2021-02-08 2022-08-11 苏州沙砾生物科技有限公司 肿瘤浸润淋巴细胞的制备方法及其用途
EP4330380A1 (en) * 2021-04-30 2024-03-06 Tigen Pharma SA Single vessel expansion of lymphocytes
US20240207319A1 (en) 2021-05-06 2024-06-27 Ludwig Institute For Cancer Research Ltd Compositions and methods for immunotherapy
WO2022269250A1 (en) * 2021-06-22 2022-12-29 Achilles Therapeutics Uk Limited A method for producing antigen-specific t cells
CN117616115A (zh) * 2021-08-03 2024-02-27 苏州沙砾生物科技有限公司 一种修饰的肿瘤浸润淋巴细胞及其用途
EP4405464A4 (en) * 2021-09-21 2025-12-03 Univ Chicago METHODS AND COMPOSITION USING PATIENT-DERIVED AUTOLOGOUS NEOANTIGENS FOR CANCER TREATMENT
CN115433713B (zh) * 2022-03-03 2023-10-27 中山大学孙逸仙纪念医院深汕中心医院 一种自体肿瘤引流淋巴结淋巴细胞的制备方法及其应用
WO2024261339A1 (en) 2023-06-23 2024-12-26 Tigen Pharma Sa Lymphocyte-stimulatory matrix (lsm) and uses thereof for expansion of lymphocyte populations
WO2025081198A1 (en) * 2023-10-13 2025-04-17 Northwestern University B cell production and expansion
WO2025131119A1 (en) * 2023-12-22 2025-06-26 Everest Medicines (China) Co., Ltd. Cancer vaccines and uses thereof

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6905680B2 (en) 1988-11-23 2005-06-14 Genetics Institute, Inc. Methods of treating HIV infected subjects
US6534055B1 (en) 1988-11-23 2003-03-18 Genetics Institute, Inc. Methods for selectively stimulating proliferation of T cells
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US5858358A (en) 1992-04-07 1999-01-12 The United States Of America As Represented By The Secretary Of The Navy Methods for selectively stimulating proliferation of T cells
US7175843B2 (en) 1994-06-03 2007-02-13 Genetics Institute, Llc Methods for selectively stimulating proliferation of T cells
US6692964B1 (en) 1995-05-04 2004-02-17 The United States Of America As Represented By The Secretary Of The Navy Methods for transfecting T cells
US7067318B2 (en) 1995-06-07 2006-06-27 The Regents Of The University Of Michigan Methods for transfecting T cells
US6291430B1 (en) 1997-09-12 2001-09-18 Ludwig Institute For Cancer Research Mage-3 peptides presented by HLA class II molecules
US6867041B2 (en) 2000-02-24 2005-03-15 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
CA2406864A1 (en) 2000-02-24 2001-08-30 Life Technologies Corporation Simultaneous stimulation and concentration of cells
US6797514B2 (en) 2000-02-24 2004-09-28 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
CA2456977C (en) 2001-08-16 2011-06-07 The Trustees Of The University Of Pennsylvania Synthesis and use of reagents for improved dna lipofection and/or slow release prodrug and drug therapies
AU2003265948B8 (en) 2002-09-06 2009-09-03 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Immunotherapy with in vitro-selected antigen-specific lymphocytes after nonmyeloablative lymphodepleting chemotherapy
US9963510B2 (en) 2005-04-15 2018-05-08 Macrogenics, Inc. Covalent diabodies and uses thereof
EP3479844B1 (en) 2005-04-15 2023-11-22 MacroGenics, Inc. Covalent diabodies and uses thereof
EP1995316A1 (de) 2007-05-25 2008-11-26 Qiagen GmbH Verfahren zur schonenden Zellaufreinigung, Zellgewinnung und Transfektion von Zellen
EP2009095A1 (en) 2007-06-28 2008-12-31 Innovalor AG Method of generating glucose-responsive cells
US8629098B2 (en) 2008-01-15 2014-01-14 Yale University Compositions and methods for adoptive and active immunotherapy
CN101824400B (zh) * 2009-03-05 2012-08-08 中国科学院微生物研究所 一种放大增殖抗原特异性t细胞的方法
US8383099B2 (en) * 2009-08-28 2013-02-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adoptive cell therapy with young T cells
BR112012029066A2 (pt) * 2010-05-14 2020-09-01 The General Hospital Corporation composições e processos de identificação de neoantígenos específicos de tumor.
WO2012044999A2 (en) 2010-10-01 2012-04-05 Ludwig Institute For Cancer Research Ltd. Reversible protein multimers, methods for their production and use
CN104769104A (zh) * 2011-12-12 2015-07-08 细胞药物有限公司 扩大t细胞的方法
AU2015273501B2 (en) * 2014-06-11 2021-01-21 Polybiocept Gmbh Expansion of lymphocytes with a cytokine composition for active cellular immunotherapy
CN107002038B (zh) * 2014-09-17 2021-10-15 约翰·霍普金斯大学 用于识别、富集和/或扩增抗原特异性t细胞的试剂和方法
US10973894B2 (en) * 2014-10-02 2021-04-13 The United States Of America, As Represented By The Secretary, Department Of Health And Human Methods of isolating T cells having antigenic specificity for a cancer-specific mutation
WO2016145578A1 (en) * 2015-03-13 2016-09-22 Syz Cell Therapy Co. Methods of cancer treatment using activated t cells
CA3022267A1 (en) * 2016-05-04 2017-11-09 Fred Hutchinson Cancer Research Center Cell-based neoantigen vaccines and uses thereof

Similar Documents

Publication Publication Date Title
JP2021501596A5 (https=)
KR102884519B1 (ko) 암을 치료하기 위한 방법
CN107206024B (zh) 改变cart细胞中的基因表达及其用途
EP3265570B2 (en) Retroviral and lentiviral vectors
JP6359520B2 (ja) Ｂ細胞成熟抗原を標的指向するキメラ抗原受容体
CN112955465A (zh) 抗tcr抗体分子及其用途
RU2575978C2 (ru) Система и способ получения и хранения активированных зрелых дендритных клеток
US20230265390A1 (en) Enhanced expansion and cytotoxicity of engineered natural killer cells and uses thereof
KR20200015467A (ko) 범용 항-cd22 키메라 항원 수용체 조작된 면역 세포
TWI334442B (en) Process for producing cytotoxic lymphocyte
KR102583138B1 (ko) T 세포를 자극 및 증대시키는 조성물 및 방법
CN111344394A (zh) 分离对p53癌症-特异性突变具有抗原特异性的t细胞的方法
TW201930591A (zh) 用於與嵌合抗原受體療法併用之免疫增強rna
JP2013014587A (ja) Ｔ細胞亜集団に特異的なモノクローナル抗体およびポリクローナル抗体の組成物および使用方法
JP2017531640A (ja) がん特異的突然変異に対し抗原特異性を有するｔ細胞受容体を単離する方法
CN109121413A (zh) 使用靶向核酸纳米载体编程治疗性细胞的组合物和方法
CN101243187B (zh) 淋巴细胞的制备方法
JP2018511320A (ja) 治療およびエピトープマッピング用Ｔ細胞の感作および増殖のためのｉｎ ｖｉｔｒｏ人工リンパ節法
WO2022125837A1 (en) Compositions and uses of cd19 targeted chimeric antigen receptor modified immune cells
JP2024050551A (ja) マウス定常領域を伴うｔｃｒを発現する細胞を選択的に増幅するための方法
JP2018510644A (ja) 治療およびエピトープマッピング用Ｔ細胞の感作および増殖のためのｉｎ ｖｉｔｒｏ人工リンパ節
CN108607094A (zh) 由基因工程化的人造抗原提呈细胞的分泌小体所构建的t细胞疫苗及其制备方法和应用
CA3214450A1 (en) Single vessel expansion of lymphocytes
EP4281544A1 (en) Engineered antigen presenting cells
CN1842346A (zh) 由巨噬细胞迁移抑制因子调节细胞毒性淋巴细胞反应